Med2Date — Clinical Guidelines
Home Family Medicine Genetic Conditions

Genetic Conditions

Last updated 31 May 2026 · Genetics

📋 Key Information Summary

📋
  • Genetic disorders are classified into chromosomal (numerical and structural), single-gene (autosomal dominant, autosomal recessive, X-linked), multifactorial/polygenic, and mitochondrial categories.
  • GPs are often the first clinicians to recognise dysmorphic features, unexplained organ dysfunction, or family history patterns suggestive of a genetic condition — early referral to clinical genetics is essential.
  • Hereditary haemochromatosis (HFE-related, C282Y homozygosity) is the most common autosomal recessive disorder in Australians of Northern European descent; diagnosis requires elevated transferrin saturation (>45%) and serum ferritin, confirmed by HFE genotyping.
  • Therapeutic venesection is first-line for haemochromatosis — aim for ferritin 50–100 µg/L; deferoxamine is reserved for iron overload where venesection is contraindicated.
  • Cystic fibrosis (CF) affects ~1 in 2,500 Australian newborns; newborn bloodspot screening is universal nationally (IRT/DNA protocol). Multidisciplinary CF centre care improves survival (median survival now >50 years).
  • CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor — Trikafta®) is PBS-listed for eligible patients aged ≥6 years with at least one F508del allele and has transformed outcomes.
  • Neurofibromatosis type 1 (NF1) follows autosomal dominant inheritance with variable expressivity; café-au-lait macules (≥6, >5 mm pre-pubertal) are the hallmark finding in childhood. Annual review for complications is recommended.
  • Haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked recessive; severity is classified by factor level (<1% severe, 1–5% moderate, >5% mild). Emicizumab (Hemlibra®) is PBS-listed for prophylaxis in severe haemophilia A.
  • Down syndrome (trisomy 21) is the most common chromosomal cause of intellectual disability in Australia; associated with congenital heart disease (~50%), thyroid dysfunction, and increased leukaemia risk.
  • Turner syndrome (45,X) presents with short stature, gonadal dysgenesis, and bicuspid aortic valve; Klinefelter syndrome (47,XXY) causes tall stature, small testes, infertility, and may present with learning difficulties or gynaecomastia at puberty.
  • Disorders of sex development (DSD) require a multidisciplinary team approach — avoid irreversible interventions without informed consent and psychosocial support.
  • Pharmacogenomics testing is increasingly accessible in Australia (e.g., CYP2D6, HLA-B*5701, DPYD); results guide drug selection and dosing, particularly for codeine, tamoxifen, abacavir, and fluoropyrimidines.
  • Aboriginal and Torres Strait Islander Australians have higher rates of certain genetic conditions (e.g., CF with unique variants, haemoglobinopathies); culturally safe genetic counselling and community engagement are paramount.

Introduction & Australian Epidemiology

Genetic conditions encompass a broad spectrum of disorders arising from alterations in chromosome structure or number, single-gene mutations, or complex interactions between multiple genes and environmental factors. In Australia, congenital and genetic conditions account for approximately 8% of hospitalisations in children and are a leading contributor to childhood mortality and morbidity.

The general practitioner (GP) plays a pivotal role in the recognition, initial workup, and long-term co-management of patients with genetic disorders. With increasing availability of genomic testing through Medicare-funded pathways and state-based clinical genetics services, GPs are uniquely positioned to identify at-risk individuals, initiate appropriate referrals, and provide ongoing care within a multidisciplinary framework.

Australian epidemiology highlights several conditions of particular relevance:

  • Cystic fibrosis: Prevalence ~1 in 2,500–3,000 live births; approximately 1 in 25 Australians of European descent are carriers.
  • Hereditary haemochromatosis: C282Y homozygosity frequency ~1 in 200 Australians of Northern European ancestry — among the highest in the world.
  • Down syndrome: ~1 in 700–1,100 live births, with maternal age-dependent risk; approximately 290 affected births per year nationally.
  • Haemophilia A: ~1 in 5,000 male births; ~2,800 people with haemophilia are registered with the Australian Bleeding Disorders Registry.
  • Turner syndrome: ~1 in 2,000–2,500 female live births.
  • Klinefelter syndrome: ~1 in 600 male births, though often under-diagnosed (only ~25% diagnosed in their lifetime).

Australia's universal newborn bloodspot screening (NBS) programme now detects cystic fibrosis, congenital hypothyroidism, phenylketonuria, and several other metabolic disorders at birth, enabling early intervention. Prenatal screening options have also expanded with non-invasive prenatal testing (NIPT) becoming widely available in the private sector.

🏥
All Australian states and territories have publicly funded Clinical Genetics Services accepting GP referrals. Patients should not need to pay for initial genetic counselling or diagnostic testing through these services. Referral templates are available via each state's genetics service website.

Classification of Genetic Disorders

Understanding the classification of genetic disorders is fundamental to accurate diagnosis, recurrence risk counselling, and selection of appropriate genetic testing strategies.

Category Mechanism Examples Recurrence Risk
Chromosomal — Numerical Aneuploidy (extra or missing chromosomes) due to non-disjunction Down syndrome (trisomy 21), Turner syndrome (45,X), Klinefelter syndrome (47,XXY), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13) Generally low (1–2% above background) unless a parent carries a balanced rearrangement
Chromosomal — Structural Deletions, duplications, translocations, inversions, ring chromosomes DiGeorge syndrome (22q11.2 deletion), Cri du chat (5p deletion), Williams syndrome (7q11.23 deletion) Depends on whether de novo or inherited from a balanced carrier
Single-gene — Autosomal Dominant (AD) Single mutant allele on an autosome sufficient to cause disease Neurofibromatosis type 1, Huntington disease, Marfan syndrome, hereditary haemochromatosis (compound het) 50% per offspring if one parent affected
Single-gene — Autosomal Recessive (AR) Two mutant alleles required (homozygous or compound heterozygous) Cystic fibrosis, hereditary haemochromatosis (HFE C282Y homozygous), phenylketonuria, sickle cell disease 25% per offspring if both parents carriers; 50% carriership
Single-gene — X-linked Recessive Mutant gene on the X chromosome; manifests in males, carrier females usually unaffected Haemophilia A & B, Duchenne/Becker muscular dystrophy, red-green colour blindness, G6PD deficiency Carrier mother: 50% of sons affected, 50% of daughters carriers
Multifactorial / Polygenic Interaction of multiple genes with environmental factors Congenital heart defects, neural tube defects, diabetes mellitus (type 1 & 2), asthma, many common cancers Empiric recurrence risks based on family studies (e.g., ~3% for NTDs after one affected child)
Mitochondrial Mutations in mitochondrial DNA; maternal inheritance MELAS, MERRF, Leber hereditary optic neuropathy All offspring of affected mothers may inherit; variable heteroplasmy affects severity

When to Suspect a Genetic Condition in Primary Care

  • Dysmorphic features or congenital anomalies in a child
  • Unexplained intellectual disability or developmental delay
  • Recurrent pregnancy losses (≥3) — consider parental karyotype
  • Family history of a known genetic condition or consanguinity
  • Early-onset disease (e.g., breast cancer <40 years, colorectal cancer <50 years)
  • Unusual drug reactions suggesting pharmacogenomic variants
  • Ethnicity-specific screening triggers (e.g., Ashkenazi Jewish ancestry, Mediterranean, Southeast Asian haemoglobinopathy screen)
⚠️
Referral threshold: Any suspicion of a genetic condition warrants referral to a state Clinical Genetics Service. Do not delay referral while awaiting investigation results — genetics teams can guide the optimal testing strategy and provide counselling simultaneously.

Hereditary Haemochromatosis

Hereditary haemochromatosis (HH) is the most common autosomal recessive genetic disorder in Australians of Northern European descent. The HFE gene (chromosome 6p) C282Y mutation accounts for >90% of cases in Australia. Homozygous C282Y individuals have lifelong increased intestinal iron absorption leading to progressive iron overload affecting the liver, heart, pancreas, joints, and endocrine organs.

Epidemiology in Australia

  • C282Y homozygosity frequency: ~1 in 200 people of Northern European descent
  • Carrier frequency: ~1 in 8–10 (highest in people of Celtic/Irish ancestry)
  • Penetrance for iron overload: ~50% in males, lower in females (menstrual losses provide partial protection)
  • Clinical disease penetrance (symptoms): estimated at 28% in males, 1% in females
  • Indigenous Australians: very low prevalence of C282Y; iron overload in ATSI populations more commonly related to dietary/environmental factors or other genetic variants

Diagnostic Criteria & Investigations

Diagnosis is based on a combination of iron studies and genetic testing:

Essential Transferrin saturation (TSAT) Fasting sample preferred. TSAT >45% is abnormal and warrants HFE genotyping. MBS item 66070.
Essential Serum ferritin Elevated >300 µg/L (males) or >200 µg/L (females) is suggestive. Markedly elevated >1,000 µg/L indicates high risk of hepatic fibrosis.
Essential HFE genotyping (C282Y, H63D, S65C) Medicare-rebatable when iron studies are abnormal. MBS item 73287. Available through major pathology providers.
Available Liver iron concentration (MRI or biopsy) MRI-FerriScan® for non-invasive quantification. Liver biopsy reserved for suspected cirrhosis or co-existing liver disease.
Available Liver elastography (FibroScan®) Non-invasive assessment of hepatic fibrosis. Recommended if ferritin >1,000 µg-L or ALT elevated.
Available Fasting glucose, HbA1c, LFTs, cardiac MRI Baseline organ assessment: hepatocellular carcinoma screen if cirrhosis present, endocrine panel (testosterone, TSH, cortisol).

Management

First-Line: Therapeutic Venesection

Therapeutic venesection (phlebotomy) is the mainstay of treatment and is the most effective means of reducing body iron stores.

  • Induction phase: Remove 500 mL of blood weekly (removes ~250 mg of iron per session) until ferritin <50 µg/L. This typically requires 15–30 sessions over 3–6 months.
  • Maintenance phase: Venesection every 2–4 months to maintain ferritin 50–100 µg/L. Frequency is individualised based on re-accumulation rate.
  • Ferritin <30 µg/L indicates excessive depletion — extend interval.
  • Venesection can be performed at Red Cross Lifeblood donor centres (free) once a GP management plan is in place and the patient meets eligibility criteria (Hb ≥110 g/L).
💊
Deferoxamine (Desferrioxamine)
Desferal® · Iron chelator
Indication Iron overload when venesection is contraindicated (severe anaemia, heart failure, poor venous access)
Adult dose 20–40 mg/kg/day SC infusion over 8–12 hours, 5–7 days/week; or 1 g IV over 4 hours in acute settings
Key monitoring Serum ferritin, iron studies every 3 months; audiometry and ophthalmology annually; renal function
Renal adjustment Use with caution if eGFR <30 mL/min; dose reduction required
PBS status ✔ PBS Authority Required
✅
Screening first-degree relatives: All first-degree relatives of a confirmed C282Y homozygote should be offered HFE genotyping and iron studies. Cascade screening is the most cost-effective strategy for case detection and prevents organ damage through early intervention.

Cystic Fibrosis

Cystic fibrosis (CF) is the most common life-limiting autosomal recessive condition in Australians of European descent, caused by mutations in the CFTR gene on chromosome 7q31. Over 2,000 CFTR mutations have been identified; F508del is the most common, present on at least one allele in ~70% of Australian CF patients. CF affects epithelial ion transport across the lungs, pancreas, liver, sweat glands, and reproductive tract.

Diagnosis

In Australia, CF is detected primarily through:

  • Newborn bloodspot screening (NBS): Universal across all states and territories since ~2008. Uses an IRT/DNA two-tier protocol. Positive screens are confirmed with sweat chloride testing at an accredited CF centre.
  • Sweat chloride test: ≥60 mmol/L is diagnostic; 30–59 mmol/L is intermediate (requires further workup including CFTR genotyping). Gold standard when performed on ≥100 mg sweat using pilocarpine iontophoresis.
  • CFTR genotyping: Identifies causative mutations; essential for eligibility assessment for CFTR modulator therapy.
  • Screening of relatives: Carrier testing for partners of known CF carriers (expanded carrier screening panels increasingly available).

Key Manifestations & Monitoring

System Manifestation Monitoring Frequency
Respiratory Bronchiectasis, chronic Pseudomonas infection, ABPA, pneumothorax, haemoptysis Spirometry every visit (quarterly); sputum culture at least quarterly; CT chest annually or as indicated
Gastrointestinal Pancreatic insufficiency (85–90%), CF-related liver disease, distal intestinal obstruction syndrome (DIOS), CF-related diabetes (CFRD) Faecal elastase at diagnosis; annual fasting glucose/HbA1c from age 10; liver function annually
Nutritional Fat-soluble vitamin deficiency (A, D, E, K), failure to thrive Annual vitamin levels; dietitian review every 3–6 months; BMI tracking
Endocrine CFRD, bone disease (osteoporosis) Annual DXA from age 18; oral glucose tolerance test from age 10
Reproductive 97–98% of males are infertile (CBAVD); reduced fertility in females Reproductive counselling from adolescence

CFTR Modulator Therapy

CFTR modulators have revolutionised CF care. Eligibility is determined by CFTR genotype.

💊
Elexacaftor / Tezacaftor / Ivacaftor
Trikafta® · CFTR modulator (corrector + potentiator)
Eligibility Patients ≥6 years with at least one F508del allele (or responsive mutation per PBS criteria)
Adult dose 2 tablets (elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning + 1 tablet (ivacaftor 150 mg) in the evening, with fat-containing food
Key side effects Hepatotoxicity (monitor LFTs at baseline, every 3 months for first year, then annually); rash; cataracts (paediatric screening)
Drug interactions CYP3A inhibitors (azoles, macrolides) — dose adjustment required. Avoid strong CYP3A inducers (rifampicin, carbamazepine).
PBS status ✔ PBS Authority Required (Section 100 — Highly Specialised Drugs)
💊
Ivacaftor
Kalydeco® · CFTR potentiator
Eligibility Patients ≥4 months with gating mutations (e.g., G551D, G1244E, G1349D, etc.)
Adult dose 150 mg PO every 12 hours with fat-containing food
PBS status ✔ PBS Authority Required (Section 100)

Pulmonary Management

  • Airway clearance: Daily physiotherapy (oscillating PEP devices, hypertonic saline nebulisation, autogenic drainage) — CF centre physiotherapist to prescribe regimen.
  • Chronic Pseudomonas aeruginosa: Inhaled tobramycin (TOBI® 300 mg nebulised BD, alternating 28 days on/28 days off) ± inhaled colistimethate. PBS-listed.
  • Acute pulmonary exacerbations: Dual IV anti-pseudomonal antibiotics (e.g., ceftazidime + tobramycin) for 14 days, guided by sputum culture and sensitivity.
  • CF-related diabetes: Managed by CF/endocrine team; insulin is the mainstay. Oral hypoglycaemics have limited role.
🚨
Infection control: Patients with CF must be segregated in hospital settings (single rooms) to prevent cross-infection with transmissible organisms (Pseudomonas aeruginosa, Burkholderia cepacia complex, non-tuberculous mycobacteria). Strict hand hygiene and mask policies apply. No patient-to-patient contact is advised, including in CF clinic waiting rooms.

Neurofibromatosis

Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant conditions, with an incidence of approximately 1 in 2,500–3,000 live births. It is caused by loss-of-function mutations in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin — a tumour suppressor that negatively regulates the RAS-MAPK signalling pathway. NF1 demonstrates variable expressivity, even within families.

Diagnostic Criteria (NIH Consensus — Revised)

Diagnosis requires ≥2 of the following (or a known pathogenic NF1 variant):

  • ≥6 café-au-lait macules (≥5 mm pre-pubertal, ≥15 mm post-pubertal)
  • ≥2 neurofibromas of any type, or ≥1 plexiform neurofibroma
  • Axillary or inguinal freckling
  • Optic pathway glioma
  • ≥2 Lisch nodules (iris hamartomas) on slit-lamp examination
  • Characteristic osseous lesion (sphenoid wing dysplasia, pseudarthrosis of long bone)
  • First-degree relative with NF1 by the above criteria
💡
Children with NF1 may not meet diagnostic criteria at birth. Café-au-lait macules are typically present from infancy; other features accrue over time. Molecular testing (NF1 gene sequencing/deletion analysis) can confirm diagnosis in ambiguous cases and is available through Clinical Genetics Services in all Australian states.

Key Complications & Surveillance

Complication Lifetime Risk Surveillance Recommendation
Optic pathway glioma ~15% (mostly in first 6 years) Annual ophthalmological assessment (visual acuity, visual fields) until age 8; MRI if symptomatic
Learning difficulties 40–60% Developmental screening at each visit; neuropsychological assessment at school entry; educational support referrals
Scoliosis 10–30% Annual spinal examination during growth; orthopaedic referral if detected
Hypertension Up to 30% Blood pressure measurement at every visit from diagnosis; consider renal artery stenosis or phaeochromocytoma if resistant
Malignant peripheral nerve sheath tumour (MPNST) ~8–13% Educate patients to report rapid growth, pain, or neurological change in existing neurofibromas; MRI for suspected transformation
Pheochromocytoma ~0.1–5.7% Annual blood pressure; 24-hour urinary catecholamines if symptomatic (hypertension, palpitations, sweating)
Breast cancer Up to 5× increased risk (before age 50) Annual breast MRI from age 30 (in line with eviQ/cancer genetics guidelines)

Management Principles

  • Coordinated multidisciplinary care: Best delivered through NF clinics (available at major paediatric and adult tertiary hospitals in each state).
  • Plexiform neurofibromas: Symptomatic plexiform neurofibromas may respond to MEK inhibitor therapy (selumetinib — available through compassionate access or clinical trials in Australia).
  • Genetic counselling: Essential for family planning. 50% recurrence risk. Prenatal testing and preimplantation genetic testing (PGT-M) are available options.
  • Psychosocial support: Visible tumours and cosmetic concerns significantly impact quality of life; refer to psychology/counselling services proactively.

Haemophilia

Haemophilia A (factor VIII deficiency) and haemophilia B (factor IX deficiency) are X-linked recessive bleeding disorders. Haemophilia A is four times more common than haemophilia B. In Australia, approximately 2,800 people are registered with the Australian Bleeding Disorders Registry (ABDR).

Severity Classification

Mild
Factor Level >5–40%
Bleeding after surgery, dental procedures, or significant trauma. May not present until adulthood. Spontaneous bleeding rare.
Setting: GP co-management with haematology; treatment at time of bleeding or procedures only
Moderate
Factor Level 1–5%
Spontaneous bleeding uncommon but may occur with minor trauma. Haemarthrosis and muscle bleeds possible. Usually diagnosed in early childhood.
Setting: Haemophilia Treatment Centre (HTC) co-management; may need prophylaxis if recurrent bleeds
Severe
Factor Level <1%
Spontaneous haemarthroses, deep muscle bleeds, intracranial haemorrhage risk. Target joints develop if bleeds recurrent. Arthropathy by adolescence without prophylaxis.
Setting: Managed exclusively at an HTC; lifelong prophylaxis required

Treatment

💊
Emicizumab
Hemlibra® · Bispecific monoclonal antibody (factor VIIIa mimetic)
Indication Prophylaxis in severe haemophilia A (with or without factor VIII inhibitors)
Dose Loading: 3 mg/kg SC weekly × 4 weeks; Maintenance: 1.5 mg/kg SC every week, OR 3 mg/kg every 2 weeks, OR 6 mg/kg every 4 weeks
Advantages Subcutaneous (not IV); extended half-life (~28 days); effective even in inhibitor patients; significantly reduces bleed rate
Key caution Activated prothrombin complex concentrate (aPCC / FEIBA®) contraindicated concurrently — thrombotic microangiopathy risk. Use recombinant factor VIIa for breakthrough bleeds.
PBS status ✔ PBS Authority Required (Section 100 — Highly Specialised Drugs)
💊
Recombinant Factor VIII (various)
Advate® / Kogenate® / Refacto® · Factor VIII replacement
Prophylaxis dose 25–40 IU/kg IV 3 times/week or every other day (standard half-life); 50 IU/kg every 3–5 days (extended half-life, e.g., Adynovate®)
On-demand / breakthrough Minor bleeds: 15–25 IU/kg; Major bleeds/surgery: 40–50 IU/kg; repeat per clinical response
PBS status ✔ PBS Authority Required (Section 100)

GP Role in Haemophilia Management

  • Immunisations: Intramuscular (IM) injections can be given after factor replacement or with pressure; subcutaneous vaccines preferred where possible.
  • Avoid NSAIDs and antiplatelet agents unless discussed with the haemophilia treatment centre. Paracetamol is safe. Selective COX-2 inhibitors may be used cautiously for mild haemophilia.
  • Dental care: Regular preventive dentistry; coordinate with HTC for any extractions.
  • Von Willebrand disease (vWD): The most common inherited bleeding disorder (~1 in 100 prevalence for type 1); mild vWD is managed in primary care with desmopressin (DDAVP) testing and specialist input.
  • Carrier testing and genetic counselling for affected families — 50% of carrier females may have low factor levels and may bleed excessively.
⚠️
Intracranial haemorrhage: Any head injury in a patient with severe haemophilia warrants immediate factor replacement (do not wait for imaging) and emergency department assessment. Keep factor concentrate at home for emergency use.

Down Syndrome (Trisomy 21)

Down syndrome (DS) is the most common chromosomal cause of intellectual disability, occurring in approximately 1 in 700–1,100 live births in Australia. Around 95% of cases result from free trisomy 21 (non-disjunction), 3–4% from Robertsonian translocation, and 1–2% from mosaicism. The incidence increases with advancing maternal age.

Associated Medical Conditions & Screening Schedule

Condition Prevalence Screening / Investigation Frequency
Congenital heart disease ~40–50% Echocardiogram in neonatal period (even if asymptomatic) At birth; repeat if clinical concern; cardiology follow-up per defect
Hypothyroidism ~15–20% (congenital + acquired) TFTs (TSH, fT4) — already covered by NBS; repeat annually Annually lifelong
Coeliac disease ~5–16% Anti-tTG IgA antibodies; small bowel biopsy if positive Screen at 2–3 years, then if symptomatic; consider repeat in adolescence
Hearing loss ~75% (conductive ± sensorineural) Audiological assessment; ENT review for glue ear Every 6 months until age 3, then annually
Visual impairment ~60% (refractive errors, strabismus, cataracts) Ophthalmological assessment At 6 months, then annually until 5 years, then every 2 years
Atlantoaxial instability ~10–20% radiological; ~1–2% symptomatic Cervical spine X-ray before contact sports or surgical intubation As needed; clinical vigilance for myelopathic signs
Leukaemia 10–20× increased risk (ALL and AML, especially transient myeloproliferative disorder in neonates) FBC if unwell; no routine screening required Clinical vigilance
Obstructive sleep apnoea ~50–75% Polysomnography or overnight oximetry; ENT assessment Screen by age 4; repeat if symptoms develop
Behavioural / psychiatric ASD ~16–18%; ADHD; regression (dissociative disorder) in adolescents/young adults Developmental surveillance; behavioural assessment Ongoing; specific concern-driven referral

GP Management Points

  • Implement the DS Health Surveillance Guidelines (published by the RACP Down Syndrome Clinical Interest Group) as a structured care plan.
  • Coordinate with paediatrician, allied health (speech pathology, physiotherapy, occupational therapy), and NDIS early childhood early intervention (ECEI) providers.
  • Flu vaccination is recommended annually; pneumococcal vaccination per ATAGI schedule for those with cardiac or respiratory comorbidities.
  • Adults with DS are at increased risk of early-onset Alzheimer disease (particularly those with APP gene on chromosome 21). Monitor for cognitive decline from age 40.
  • Life expectancy in Australia now exceeds 60 years with appropriate medical care and community support.
📋
Prenatal screening options: Australian guidelines recommend offering all pregnant women screening for trisomy 21. Options include first-trimester combined screening (NT + serum markers at 11–13 weeks) and NIPT (available from 10 weeks gestation; privately funded ~0–0 but some public hospitals now offer it). Confirmatory diagnosis requires invasive testing (CVS or amniocentesis).

Turner Syndrome & Klinefelter Syndrome

Turner Syndrome (45,X and Variants)

Turner syndrome (TS) affects approximately 1 in 2,000–2,500 live-born females. It results from complete or partial loss of one X chromosome. Mosaic forms (45,X/46,XX) account for ~30% of cases and may have a milder phenotype.

Key Features

  • Short stature: The most universal feature; average adult height without treatment ~143 cm (–3 SD). GH therapy can add 5–8 cm.
  • Gonadal dysgenesis: 85–90% have streak gonads; most require oestrogen/progesterone replacement for puberty induction and bone health. Only ~2–5% achieve spontaneous pregnancy.
  • Cardiac: Bicuspid aortic valve (~30%), coarctation of aorta (~10%), aortic root dilation — lifelong cardiac surveillance essential. Risk of aortic dissection.
  • Renal: Horseshoe kidney, collecting system anomalies (~30–40%).
  • Autoimmune: Hypothyroidism (Hashimoto's), coeliac disease, type 1 diabetes.
  • Other: Recurrent otitis media, sensorineural hearing loss, lymphoedema (neonatal), webbed neck, shield chest, scoliosis.
💊
Somatropin (Growth Hormone)
Genotropin® / Norditropin® / Omnitrope® · Recombinant growth hormone
Indication Growth failure in Turner syndrome
Dose 0.045–0.050 mg/kg/day SC; start at diagnosis of short stature, continue until near-final height or bone age >14 years
Monitoring Height velocity every 6 months; IGF-1 levels; glucose/HbA1c; scoliosis check; thyroid function
PBS status ✔ PBS Authority Required

Turner Syndrome — Surveillance Checklist (GPs)

Cardiac imaging
Echocardiogram at diagnosis; MRI aorta every 5–10 years (more frequently if aortopathy)
Thyroid function
TSH, fT4 annually
Blood pressure
Every visit; 24-hour ABPM if elevated
Glucose/HbA1c
OGTT every 3–5 years from age 16; annually if BMI >30 or family history of T2DM
Renal ultrasound
Once at diagnosis
Hearing assessment
Every 3–5 years; annually from age 45
Bone density
DXA if risk factors or oestrogen non-adherence; ensure adequate calcium + vitamin D

Klinefelter Syndrome (47,XXY)

Klinefelter syndrome (KS) is the most common sex chromosome aneuploidy, affecting approximately 1 in 600 males. Despite this, it remains significantly under-diagnosed, with an estimated 75% of affected individuals never identified. Diagnosis is often delayed until puberty (gynaecomastia, small testes) or adulthood (infertility).

Key Features

  • Gonadal: Small, firm testes (typically <4 mL volume after puberty); hypergonadotropic hypogonadism; azoospermia in ~95%; infertility is the presenting feature in ~30% of diagnosed cases.
  • Growth: Tall stature with disproportionately long legs (increased sitting height:standing height ratio). Average adult height ~185 cm.
  • Gynaecomastia: ~50% of cases; increased risk of male breast cancer (20–50× compared to 46,XY males).
  • Learning & behaviour: Verbal processing difficulties, language delay, increased rates of ADHD, ASD (~5–10%), anxiety, and social difficulties. IQ is usually in the low-normal range.
  • Metabolic: Increased risk of metabolic syndrome, type 2 diabetes, VTE, osteoporosis (if untreated hypogonadism).

Management — Testosterone Replacement

💊
Testosterone (various formulations)
Reandron 1000® / Testogel® / Primoteston Depot®
Indication Testosterone replacement in KS with biochemically confirmed hypogonadism (elevated FSH/LH, low testosterone)
Reandron 1000 (preferred) 1000 mg IM deep gluteal injection: loading dose at week 0, 6, then every 10–14 weeks
Testogel (alternative) 50 mg (5 g sachet) applied daily to shoulders/upper arms; adjust to achieve trough testosterone in mid-normal range
Monitoring Testosterone levels (trough before next Reandron dose), FBC (polycythaemia risk), lipids, LFTs, PSA from age 50, bone density
PBS status ✔ PBS Authority Required
💡
Fertility in KS: Micro-TESE (testicular sperm extraction) with ICSI has achieved biological paternity in ~40–50% of men with non-mosaic KS. Referral to a reproductive endocrinologist should be offered early, ideally in late adolescence, as sperm retrieval success decreases with age. Testosterone therapy may suppress residual spermatogenesis — fertility preservation should be discussed before commencing treatment.

Disorders of Sex Development (DSD)

Disorders of sex development (DSD) are a group of congenital conditions in which development of chromosomal, gonadal, or anatomical sex is atypical. The estimated incidence is approximately 1 in 4,500 live births (for conditions presenting with genital ambiguity); some DSD conditions are considerably more common when broader definitions are used.

Classification

Category Examples Key Features
Sex chromosome DSD 45,X/46,XY (mixed gonadal dysgenesis); 46,XX/46,XY (chimerism) Variable genitalia; may present with ambiguous genitalia at birth or atypical puberty
46,XY DSD Androgen insensitivity syndrome (AIS); 5α-reductase deficiency; gonadal dysgenesis; disorders of testosterone synthesis Complete AIS: female phenotype, undescended testes, absent uterus; partial AIS: variable ambiguity
46,XX DSD Congenital adrenal hyperplasia (CAH — 21-hydroxylase deficiency, 11β-hydroxylase deficiency); aromatase deficiency; maternal androgen exposure CAH is the most common cause of ambiguous genitalia in 46,XX individuals (~1 in 15,000); virilised external genitalia with normal internal female structures

Approach to Suspected DSD

1
Recognise & Refer
Any newborn with ambiguous genitalia (Prader scale assessment) requires urgent referral to a tertiary paediatric centre with a DSD multidisciplinary team (MDT). Do not assign sex in the delivery suite.
2
Urgent Investigations
Karyotype (or FISH for SRY), 17-hydroxyprogesterone, electrolytes (Na⁺, K⁺), glucose, cortisol, ACTH, testosterone, DHT, pelvic ultrasound. Exclude salt-wasting CAH (life-threatening adrenal crisis in neonates).
3
MDT Assessment
Team includes: endocrinologist, urologist/paediatric surgeon, geneticist, psychologist, ethicist, social worker. Involve the family in all discussions.
4
Gender Assignment
Assign sex of rearing based on diagnosis, anatomy, likely fertility potential, and family preference. Irreversible surgical interventions are increasingly deferred until the individual can participate in decision-making, in line with contemporary Australian and international guidelines.

Congenital Adrenal Hyperplasia (CAH) — Key Management Points

💊
Hydrocortisone
Cortef® · Glucocorticoid replacement
Paediatric dose 10–15 mg/m²/day PO in 3 divided doses (must mimic physiological cortisol rhythm)
Adult dose 15–25 mg PO daily in 2–3 divided doses (morning-weighted)
Sick day rules Triple dose during febrile illness; IM hydrocortisone 50 mg (infant) or 100 mg (child/adult) for vomiting/inability to take oral — emergency injection kit to be carried at all times
PBS status ✔ PBS General Benefit
💊
Fludrocortisone
Florinef® · Mineralocorticoid replacement
Paediatric dose 50–200 µg PO daily; adjusted by plasma renin activity
Note Salt supplementation (1–2 g NaCl/day) often needed in infants
PBS status ✔ PBS General Benefit
🚨
Neonatal salt-wasting crisis: Classic CAH (salt-wasting form) presents at 1–3 weeks of life with vomiting, dehydration, hyponatraemia, hyperkalaemia, and potentially fatal cardiovascular collapse. This is a medical emergency — treat with IV normal saline bolus and IV hydrocortisone immediately. All newborns with ambiguous genitalia and all unwell neonates must have CAH excluded.

Pharmacogenomics

Pharmacogenomics (PGx) is the study of how genetic variation influences individual drug response — encompassing efficacy, dosing, and adverse drug reactions (ADRs). Advances in genomic medicine have made PGx testing increasingly accessible in Australian clinical practice, with several tests now Medicare-rebatable or available through public hospital services.

Key Pharmacogenomic Associations in Australian Practice

Gene Drug(s) Affected Clinical Impact Testing Availability
HLA-B*5701 Abacavir (HIV treatment) Carriers at high risk of hypersensitivity reaction (fever, rash, GI symptoms, potentially fatal). Mandatory testing before abacavir initiation in Australia. PBS-rebatable. MBS item 73310 — Medicare-rebatable
CYP2D6 Codeine, tramadol, tamoxifen, ondansetron, some antidepressants, antipsychotics Poor metabolisers: no analgesic effect from codeine; Ultra-rapid metabolisers: risk of respiratory depression (especially children — codeine contraindicated <12 years per TGA). Tamoxifen: poor metabolisers may have reduced efficacy in breast cancer. Available through private pathology (~0–0); some hospital genetics services
DPYD Fluoropyrimidines (5-FU, capecitabine) DPYD deficiency: severe/fatal toxicity (myelosuppression, mucositis, neurotoxicity). Pre-treatment testing now endorsed by eviQ/Cancer Australia for all patients. Available through oncology services; private pathology; MBS item in development
HLA-B*1502 Carbamazepine Strongly associated with Stevens-Johnson syndrome/toxic epidermal necrolysis in Southeast Asian and Han Chinese populations. TGA recommends testing before carbamazepine in at-risk ethnic groups. Available through pathology; MBS item 73305
CYP2C19 Clopidogrel, voriconazole, some PPIs Poor metabolisers: clopidogrel may be ineffective (prodrug activation reduced) → increased cardiovascular event risk. Alternative antiplatelet agents (ticagrelor, prasugrel) preferred. Available through private pathology; hospital services
CYP2C9 / VKORC1 Warfarin Variants affect dose requirements and time in therapeutic range. PGx-guided dosing algorithms available but not yet standard practice in Australia. Available through private pathology
NUDT15 Azathioprine, 6-mercaptopurine Variants cause severe myelosuppression, particularly relevant in inflammatory bowel disease and leukaemia treatment. Testing increasingly standard before initiation. Available through gastroenterology/haematology services

Practical Points for GPs

  • Pharmacogenomic results are generally lifelong — they do not change. Encourage patients to carry a card or have results recorded in their My Health Record.
  • Pre-emptive PGx panel testing (testing multiple genes at once) is increasingly available and may be cost-effective before starting medications with known PGx associations.
  • The Pharmaceutical Society of Australia (PSA) and RACGP support the integration of PGx into primary care practice, particularly for polypharmacy patients and those with unexplained ADRs.
  • Consult the CPIC (Clinical Pharmacogenetics Implementation Consortium) guidelines for evidence-based dose adjustments based on genotype.
  • Codeine is contraindicated in children <12 years and in breastfeeding mothers of CYP2C19 ultra-rapid metaboliser genotype — TGA advisory (2015, updated 2019).
✅
Future direction: The Australian Genomics Health Alliance and Genomics England's 100,000 Genomes project are paving the way for routine genomic medicine integration. GPs can expect PGx to become part of standard prescribing workflows within the next 5–10 years. Start by familiarising yourself with HLA-B*5701 (abacavir) and DPYD (fluoropyrimidines) testing, which are already mandated in clinical practice.

Genetic Investigations — Overview for Primary Care

Genetic testing is now more accessible than ever in Australia. Understanding the types of tests and when to order them (versus when to refer to genetics) is a core GP competency.

Essential Karyotype (chromosome analysis) Detects aneuploidy and large structural rearrangements. Turnaround: 7–14 days. Indicated in suspected Down syndrome, Turner/Klinefelter, recurrent pregnancy loss. Available through all pathology providers. MBS item 73281.
Essential Chromosomal microarray (CMA) Detects submicroscopic copy number variants (deletions/duplications). First-line test for intellectual disability, autism spectrum disorder, and multiple congenital anomalies. Replaces karyotype in many scenarios. MBS item 73290.
Essential Single-gene sequencing Targeted testing when a specific condition is suspected (e.g., HFE genotyping, CFTR sequencing, NF1 gene analysis, F8/F9 for haemophilia). Medicare-rebatable with appropriate clinical indication.
Available Whole exome sequencing (WES) / Whole genome sequencing (WGS) Available through Clinical Genetics Services and research programmes (e.g., Australian Genomics). Typically used when targeted testing has been non-diagnostic. May identify variants of uncertain significance (VUS). Funding varies — may be research-funded or via hospital/genetics service.
Available Non-invasive prenatal testing (NIPT) Cell-free fetal DNA from maternal blood. Screens for trisomy 21, 18, 13 and sex chromosome aneuploidies. Sensitivity >99% for trisomy 21. Available from 10 weeks gestation. Privately funded (~0–0). Not currently Medicare-rebatable but offered in some public hospitals.
Available Pharmacogenomic panels Multi-gene panels (CYP2D6, CYP2C19, DPYD, HLA-B*5701, etc.) available through private pathology and some hospital services. Cost: 0–0 for panel testing.
Referral Preimplantation genetic testing (PGT-M / PGT-SR) Available at accredited IVF centres for known monogenic conditions or structural rearrangements. Requires prior genetic diagnosis and counselling. Medicare-rebatable component under ART MBS items.
📋
Informed consent for genetic testing: All genetic testing requires informed consent that addresses: the nature of the test, possible outcomes (including variants of uncertain significance), implications for family members, data storage and privacy, and the option to decline. The Human Genetics Society of Australasia (HGSA) provides consent templates.

Monitoring & Long-Term Care

Many genetic conditions require lifelong monitoring. The GP plays a central role in coordinating this surveillance, often in partnership with specialist teams.

Principles of Long-Term Monitoring

  • Structured care plans: Use condition-specific management guidelines (e.g., DS Health Surveillance, CF standards of care, NF1 surveillance guidelines) to create recall systems in your practice software.
  • Transition of care: Adolescents with genetic conditions require structured transition from paediatric to adult services. Key elements include: preparation (from age 12–14), transfer of care (usually 16–18), and integration into adult services. The RACP Transition Care guidelines provide a framework.
  • Genetic family history updates: Revisit family history at major life events (pregnancy planning, new family diagnoses, changes in family structure).
  • Cascade screening: When a new genetic diagnosis is confirmed, assist the family in identifying at-risk relatives who should be offered testing (e.g., haemochromatosis, CF carrier testing, familial cancer syndromes).
  • Psychosocial support: Living with a genetic condition carries significant psychosocial burden — stigma, anxiety about children's risk, grief, and family dynamics. Proactive mental health screening and referral to support organisations (e.g., Genetic Support Network of Victoria, Cystic Fibrosis Australia, Haemophilia Foundation Australia) should be embedded in care.

Key Organisations for Patient Support

Condition Organisation Resource
General genetics Human Genetics Society of Australasia (HGSA) hgsa.org.au
Cystic fibrosis Cystic Fibrosis Australia cfa.org.au
Haemophilia Haemophilia Foundation Australia haemophilia.org.au
Down syndrome Down Syndrome Australia downsyndrome.org.au
Neurofibromatosis Children's Tumour Foundation of Australia ctf.org.au
Haemochromatosis Haemochromatosis Australia haemochromatosis.org.au
DSD Androgen Insensitivity Syndrome Support Group Australia (AISSG) aissg.org
Turner syndrome Turner Syndrome Association of Australia tsaa.org.au

Special Populations

🤰

Pregnancy

Haemochromatosis: Ferritin falls physiologically in pregnancy; venesection is generally deferred. Monitor iron studies postpartum.
CF carriers / affected women: Preconception counselling essential. CF pregnancies are high-risk (increased preterm delivery, gestational diabetes). Multidisciplinary obstetric/CF team care recommended.
Turner syndrome: Pregnancy possible via oocyte donation; requires cardiac assessment (aortic size index) before and during pregnancy due to dissection risk.
Haemophilia carriers: ~50% of carrier females have reduced factor levels. Factor levels should be checked in pregnancy; epidural placement requires factor level >50%. Neonatal care plan for potential affected male required.
CAH: Continue glucocorticoid and mineralocorticoid replacement throughout pregnancy. Hydrocortisone is preferred (does not cross placenta). Dose may need adjustment in the third trimester.
Teratogenicity: Some genetic condition medications are teratogenic (e.g., mycophenolate in some autoimmune contexts). Review all medications at preconception planning.
👶

Paediatrics

Newborn screening: All Australian newborns receive bloodspot screening for CF, PKU, CH, galactosaemia, and other conditions. Positive results require urgent follow-up by the relevant specialist.
Developmental surveillance: Children with genetic conditions (DS, NF1, KS, TS) require structured developmental monitoring using the ASQ-3, SDQ, and formal neuropsychological assessment as indicated.
Immunisation: Standard schedule applies to most genetic conditions. Live vaccines (MMR, varicella) may need consideration in immunocompromised states — discuss with specialist. CAH patients on high-dose steroids may need vaccination timing adjusted.
NDIS access: Children with genetic conditions causing developmental delay or disability are likely eligible for NDIS early childhood early intervention (ECEI) supports. Assist families with access requests.
School support: Individual Education Plans (IEPs) and integration aides may be needed for children with intellectual disability (DS, NF1) or learning difficulties (KS, TS).
🧓

Elderly

Down syndrome — Alzheimer disease: Nearly all individuals with DS develop Alzheimer neuropathology by age 40; clinical dementia affects ~50–70% by age 60. Monitor for cognitive and functional decline. Standard Alzheimer therapies (donepezil, rivastigmine) may be used.
Haemochromatosis: Older patients may present with established complications (cirrhosis, cardiomyopathy, diabetes). Surveillance for hepatocellular carcinoma (6-monthly AFP and ultrasound) is mandatory if cirrhosis is present.
Osteoporosis: Patients with TS, KS, and CAH on long-term glucocorticoids are at increased osteoporosis risk. DXA monitoring, calcium, vitamin D, and anti-resorptive therapy as per guidelines.
Polypharmacy: Pharmacogenomic testing may be particularly valuable in older patients with multiple medications and unexplained adverse drug reactions.
🫘

Renal Impairment

Deferoxamine: Use with caution if eGFR <30 mL/min; dose reduction required. Monitor for nephrotoxicity.
CF medications: Some antibiotics used for pulmonary exacerbations (tobramycin, colistin) are nephrotoxic — dose adjust by renal function; monitor drug levels.
Turner syndrome: Renal anomalies (horseshoe kidney) increase UTI and stone risk. Annual renal monitoring if structural abnormality present.
🫁

Hepatic Impairment

Haemochromatosis with cirrhosis: Venesection can still be performed but at a slower rate (fortnightly rather than weekly). Monitor for decompensation.
CF-related liver disease: Ursodeoxycholic acid (15–20 mg/kg/day) may slow progression. Avoid hepatotoxic agents.
CFTR modulators: Trikafta® is hepatically metabolised — LFTs must be monitored. Dose reduction or cessation if ALT >5× ULN.
🛡️

Immunocompromised

Haematological malignancy risk: Down syndrome carries increased risk of leukaemia (particularly ALL and transient myeloproliferative disorder in neonates). NF1 carries increased risk of juvenile myelomonocytic leukaemia (JMML) and MPNST.
Live vaccines: Generally safe in most genetic conditions. Exceptions: patients on high-dose corticosteroids for CAH management (>2 mg/kg/day prednisolone equivalent for >14 days) — defer live vaccines.
Post-splenectomy: Not routinely indicated for genetic conditions, but if performed (e.g., for hypersplenism in haemoglobinopathies), follow asplenia vaccination and antibiotic prophylaxis guidelines.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health — Genetic Conditions

Genetic conditions in Aboriginal and Torres Strait Islander Australians have unique epidemiological, cultural, and access considerations. A culturally safe and community-centred approach is essential.

HFE Haemochromatosis
The C282Y and H63D HFE mutations are rare in Aboriginal and Torres Strait Islander populations. Iron overload in ATSI communities is more commonly related to dietary factors, chronic liver disease (high hepatitis B prevalence in remote NT/QLD), or other non-HFE iron overload conditions. Do not assume HFE-related haemochromatosis — investigate with broader iron overload workup including HFE genotyping, serum iron studies, and hepatic assessment.
Cystic Fibrosis
CF occurs in ATSI populations but may present with different CFTR mutation profiles (higher rates of non-F508del mutations). Newborn bloodspot screening applies to all Australian newborns, including those born in remote communities — ensure timely follow-up of positive screens, which may be logistically challenging in remote settings. Delayed diagnosis has been documented in ATSI children.
Haemoglobinopathies
Alpha-thalassaemia trait is common in Aboriginal and Torres Strait Islander populations (up to 30–40% in some Northern Australian communities). Sickle cell trait and G6PD deficiency also occur. These conditions are important to identify before antimalarial prescribing, in pregnancy screening, and in neonatal jaundice management. Ensure MCH and antenatal screening programmes include haemoglobinopathy testing in ATSI populations.
Remote Access to Clinical Genetics
Specialist genetics services are concentrated in metropolitan centres. Telehealth genetics consultations are available through most state Clinical Genetics Services and are increasingly used for remote communities. Ensure interpreter services are available if English is not the patient's first language. Ring-bark genetic counselling (fly-in-fly-out genetics outreach) programmes operate in some jurisdictions (e.g., NT Genetics Service).
Cultural Safety in Genetic Counselling
Genetic concepts (e.g., carrier status, inheritance patterns) may require culturally appropriate explanations. Concepts of kinship and family differ from Western models — extended family and community may be central to decision-making. Involve Aboriginal and Torres Strait Islander health workers (AHPs/AHWs) in genetic counselling sessions. Some communities may have cultural protocols around discussing certain health conditions or family history — respect these.
Consanguinity Awareness
In some remote communities with small population sizes, consanguinity rates may be higher. This increases autosomal recessive condition risk. Approach discussions about consanguinity with cultural sensitivity and without judgement. Genetic counselling should focus on supporting informed reproductive choices.
Pharmacogenomics
ATSI populations may carry unique pharmacogenomic variants not captured in current PGx databases (which are heavily based on European data). HLA-B*5701 prevalence in ATSI populations is lower than in some other groups but still requires testing before abacavir. CYP2D6 poor metaboliser frequency may differ from European populations. Be cautious when applying PGx guidelines developed in non-ATSI populations.
Community Engagement
Genetic research and screening programmes in ATSI communities must follow NHMRC guidelines for ethical conduct (Values and Ethics: Guidelines for Ethical Conduct in Aboriginal and Torres Strait Islander Health Research). Community consent and ongoing engagement are essential. Genetic data sovereignty is an emerging concern — ensure data is stored and used with community knowledge and consent.

📚 References

  1. 1. Royal Australian College of General Practitioners (RACGP). Genomics in general practice. RACGP Specific Interests, 2023. Available from: racgp.org.au
  2. 2. Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC guidelines for gene-drug pairs. Updated 2024. Available from: cpicpgx.org
  3. 3. Gastroenterological Society of Australia (GESA). Haemochromatosis clinical practice guidelines. J Gastroenterol Hepatol. 2022.
  4. 4. Cystic Fibrosis Australia. Australian standards of care for cystic fibrosis. 9th ed. Sydney: CFA; 2023.
  5. 5. National Health and Medical Research Council (NHMRC). Values and Ethics: Guidelines for Ethical Conduct in Aboriginal and Torres Strait Islander Health Research. Canberra: NHMRC; 2018.
  6. 6. Human Genetics Society of Australasia (HGSA). Position statement: Preimplantation genetic testing. HGSA; 2023.
  7. 7. Haemophilia Foundation Australia. Guidelines for the management of haemophilia in Australia. Melbourne: HFA; 2022.
  8. 8. Down Syndrome Australia. Health care guidelines for people with Down syndrome. Melbourne: DSA; 2022.
  9. 9. Australasian Society of Clinical Immunology and Allergy (ASCIA). Pharmacogenomics and drug hypersensitivity position statement. ASCIA; 2023.
  10. 10. Therapeutics Goods Administration (TGA). Codeine: Updated recommendations for use in children. TGA Safety Advisory, 2019.
  11. 11. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework. Canberra: AIHW; 2023.
  12. 12. Clinical Oncology Society of Australia (COSA) / eviQ. DPYD testing before fluoropyrimidine chemotherapy — consensus statement. eviQ Cancer Treatments Online; 2024.
  13. 13. The Royal Australasian College of Physicians (RACP). Transition to adult health services for young people with chronic conditions. Sydney: RACP; 2020.
  14. 14. National Pathology Accreditation Advisory Council (NPAAC). Standards for the reporting of genetic tests by laboratories. Canberra: Department of Health; 2019.
  15. 15. Australian Genomics Health Alliance.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).